Alcobra Provides Update on Recent FDA Meeting and Path Forward for MDX Clinical Development Program

TEL AVIV, Israel, Jan. 09, 2017 (GLOBE NEWSWIRE) -- Alcobra Ltd. (Nasdaq:ADHD), an emerging pharmaceutical company focused on the development of new medications to treat patients with cognitive disorders, including Attention Deficit Hyperactivity...
Source: Drugs.com - New Drug Applications - Category: Drugs & Pharmacology Source Type: news